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Abstract
Leukocyte function associated antigen-1 (LFA-1) is a primary cell adhesion molecule of leukocytes
required for mediating cellular transmigration into sites of inflammation via the vascular
endothelium. A cyclic peptide, cIBR, possesses high affinity for LFA-1 and conjugation to the surface
of poly(DL-lactic-co-glycolic acid) nanoparticles can specifically target and deliver the encapsulated
agents to T cells expressing LFA-1. The kinetics of targeted nanoparticle uptake by acute
lymphoblastic leukemia T cells was investigated by flow cytometry and microscopy and compared
to untargeted nanoparticles. The specificity of targeted nanoparticles binding to the LFA-1 integrin
was demonstrated by competitive inhibition using free cIBR peptide or using the I domain of LFA-1
to inhibit the binding of targeted nanoparticles. The uptake of targeted nanoparticles was
concentration and energy dependent. The cIBR-conjugated nanoparticles did not appear to localize
with lysosomes whereas untargeted nanoparticles were detected in lysosomes in 6 hrs and steadily
accumulated in lysosomes for 24 hrs. Finally, T-cell adhesion to epithelial cells was inhibited by
cIBR-nanoparticles. Thus, nanoparticles displaying the cIBR ligand may offer a useful targeted drug
delivery system as an alternative treatment of inflammatory diseases involving transmigration of
leukocytes.
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Introduction
Leukocytes play an important role in disease defense and participate in the adaptive immune
response. Under normal conditions, leukocytes circulate between the blood stream and the
lymphatic system as non-adherent cells. 1 Upon receiving signals from inflammatory
mediators, various cell adhesion molecules are up-regulated and leukocytes are recruited to
the vascular endothelium. 1 Leukocytes selectively accumulate at sites of inflammation via
this multivalent adhesion mechanism and subsequently migrate into underlying tissues. 2
Several adhesion molecules mediate the process including members of the integrin family and
their immunoglobulin (Ig) superfamily ligands. 1, 3 The recruitment of leukocytes from the
blood stream to the inflammatory site involves a multistep adhesion cascade (e.g. tethering,
rolling, activation and arrest). The integrins playing a major role during arresting and
transmigration are LFA-1, α4β1 and α4β7 which bind to members of the immunoglobulin
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superfamily on endothelium such as ICAM-1. 4 In inflammatory diseases, the extravasation of
leukocytes into the inflammed tissues ultimately propagates further inflammation which may
lead to a chronic disease state. LFA-1 has emerged as an interesting target for treatment of
inflammatory diseases and drug delivery.
LFA-1 is constitutively expressed in a low affinity conformation on the plasma membrane of
leukocytes. 5 The ligand binding activity of LFA-1 is tightly regulated. LFA-1 activation results
in an increase in the affinity for ligand induced by a conformational change, and clustering of
integrins on the cell surface. 4 Rolling leukocytes respond to chemokines on vascular
endothelial cells by expressing specific receptors that transmit intracellular signals through G
proteins. 4 Chemokine receptor signaling changes the conformation of LFA-1 from a closed
form (low affinity conformation) on the T-cell surface to open form (high affinity
conformation) and hence enables T-cells to adhere and then migrate across the vascular wall.
LFA-1 clustering is initiated by lateral migration of integrins to form multivalent binding foci,
thus strengthening the adhesion. 6
Leukocytes express molecules from the β2 integrin subfamily which includes leukocyte
function associated antigen-1 (LFA-1, αLβ2, CD11a/CD18), MAC-1 (CD11b/CD18) and
P150, 95 (CD11c/CD18). These molecules mediate binding to the intercellular adhesion
molecule-1 (ICAM-1) Ig superfamily. 2, 3 ICAM-1 (CD54) is the major LFA-1 ligand
expressed on endothelial cells, epithelial cells and on antigen presenting cells (APC). ICAM-1
is up-regulated by proinflammatory cytokines such as IL-1, IL-4, IL-6, TNF-α and IFN-γ
during inflammation. LFA-1 binds to ICAM-1 via specific interaction between the I domain
of LFA-1 and domain 1 (D1) of ICAM-1. Blockade of this molecular interaction using
monoclonal antibodies has been shown to be efficacious against acute inflammation 7, and
autoimmune diseases such as diabetes 8, rheumatoid arthritis 9 and psoriasis 10, 11 inaddition
to suppressing allograft rejection. 12, 13
Here, a small peptide antagonist known to allosterically block binding of ICAM-1 to LFA-1
was used as a targeting ligand for nanoparticles. 14 cIBR (cyclo 1,12) Pen-PRGGSVLVTGC-
OH is a cyclic peptide derived from D1 of ICAM-1. NMR, docking experiments and
competitive inhibition by anti-LFA-1 have shown that the binding site of cIBR is on the I
domain of LFA-1. 14-16 cIBR has been characterized to bind to the L site of the I domain of
PMA activated LFA-1. 14 This peptide has been shown to interfere with T cell homotypic and
heterotypic adhesion and with mixed lymphocyte reaction. 16-18 Interestingly, cIBR has been
reported to be internalized by LFA-1 integrin on the surface of T cells, but not internalized into
LFA-1 deficient cell lines 14-15, 19, suggesting that cIBR could be used as a targeting ligand
for selective intracellular drug delivery to leukocytes.
LFA-1 mediated adhesion is mediated by integrin clustering in addition to the activation of
this receptor. Although the mechanism of clustering remains to be clarified 6, receptor
clustering appears to be the consequence of an initial high affinity interaction of LFA-1 with
multivalent ICAM-1. 5-6 Multivalent interactions of multiple ligands on nanoparticles can
increase the binding avidity by orders of magnitude. 20 In this study, cIBR peptide was
conjugated to the surface of nanoparticles to mimic the clustering of ICAM-1 and hence
increase the avidity of binding to LFA-1 on T-cells. cIBR conjugated nanoparticles (cIBR-
NPs) bound to LFA-1 on T-cells (Molt-3) more rapidly and to a greater extent compared to
untargeted nanoparticles. In addition, cIBR-NPs were shown to block the adhesion of Molt-3
cells to A549 lung epithelial cells. These findings suggest a potential dual therapeutic
mechanism for cIBR-NPs to control inflammatory diseases by blocking leukocyte adhesion
and by targeting the delivery of drugs (e.g. anti-inflammatory agents).
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cIBR peptide (Cyclo(1,12)-Pen-PRGGSVLVTGC-OH) (Mw 1,174.5) was synthesized on a
Pioneer peptide synthesizer (PerSeptive Biosystems, CA). Poly(DL-lactic-co-glycolic acid)
(50:50) with terminal carboxyl group (PLGA, inherent viscosity 0.67dL/g, Mw ∼90 kDa) was
purchased from LACTEL Absorbable Polymers International (Pelham, AL, USA).
Pluronic®F-127, Texas Red Dextran (10,000 kDa, lysine fixable) and 2′,7′-bis-(2-
carboxyethyl)-5-(and-6)-carboxyfluorescein, acetoxymethyl ester (BCECF, AM) were
purchased from Invitrogen Molecular Probes, Inc. (Carlsbad, CA, USA). Coumarin-6 was
obtained from Polysciences, Inc. (Warrington, PA, USA). Dialysis membrane (MwCO
100,000) was purchased from Spectrum laboratory Products Inc. (Rancho Dominguez, CA,
USA). RPMI 1640 medium, A549 cell line and the Molt-3 cell line were obtained from
American Type Culture Collection (Manassas, VA, USA). Phorbol 12-myristate 13-acetate
(PMA) was purchased from BIOMOL International, L.P. (Plymouth Meeting, PA).
2. Methods
2.1 PLGA nanoparticle preparation and characterization—Nanoparticles
encapsulating a fluorescent marker, coumarin-6, were formulated using a solvent displacement
method. 21 In brief, PLGA was dissolved in acetone (18 mg/ml) containing coumarin-6 (50
μg/ml). The solution was slowly transferred to a water phase containing 0.1% Pluronic®F-127-
COOH (25 ml) under mild stirring (300 RPM). Terminal hydroxyl groups on Pluronic®F-127
were converted to carboxyl groups according to a reported procedure. 22-23 The nanoparticles
spontaneously formed due to the rapid removal of acetone. Excess surfactant was removed by
dialysis against a 0.2% mannitol solution for 48 hrs.
2.2 Conjugation of cIBR peptide to PLGA-nanoparticles—Pluronic®F-127-COOH
coated PLGA nanoparticles (2.2 mg/ml) were buffered using 2-(N-morpholino)ethanesulfonic
acid (MES; pH 6.5). Nanoparticles were then incubated with 100 mM 1-Ethyl-3-[3-
dimethylaminopropyl]carbodiimide hydrochloride (EDC) and 50 mM N-
hydroxysulfosuccinimide (sulfo-NHS) for 15 min. 23 The activated carboxyl terminus of
Pluronic® F127-COOH on the surface of nanoparticles was allowed to react with the amino
terminus of the cIBR peptide (170 μM) for 12 hrs at room temperature. Conjugated NPs were
collected by centrifugation (16,089 g, 10 min) and washed three times with purified water. The
size and charge of NPs and cIBR-NPs were characterized using dynamic light scattering
(ZetaPALS, Brookhaven instrument Inc.).
The amount of free cIBR after the reaction was quantified by gradient reversed phase HPLC
(SHIMADZU) using a C18 column. The HPLC consisted of SCL-10A SHIMADZU system
controller, LC-10AT VP SHIMADZU liquid chromatograph, SIL-10A XL SHIMADZU
autoinjecter set at 10 μl injection volume, DGU-14A SHIMADZU degasser, sample cooler,
and SPD-10A SHIMADZU UV-Vis detector (220 nm). The HPLC-UV system was controlled
by a personal computer equipped with SHIMADZU class VP Software. All separations were
carried out using a Vydac® HPLC Protein and Peptide C18 column. Gradient elution was
carried out at constant flow of 1 ml/min, from 100% A to 0% A (corresponding to 0% B to
100% B) for 15 min, followed by an isocratic elution at 100% B for 3 min. Mobile phase
compositions were (A) acetronitrile-water (5:95) with 0.1% TFA and (B) acetonitrile–water
(90:10, v/v) with 0.1% trifluoroacetic acid (TFA). At the end of each analysis, the cartridge
was re-equilibrated at 1 ml/min flow rate for 13 min with A. The density of peptide on the
surface of nanoparticles was calculated from the total surface area assuming a normal Guassian
particle size distribution.
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2.3 Stimulation of LFA-1 by phorbol 12-myristate 13-acetate (PMA)—The Molt-3
cell line (1 × 106 cells/ml) was stimulated using 0.4 μM of PMA for 20 hrs. According to
previous reports, PMA is able to activate LFA-1 and improve binding to ICAM-1. 24 Cells at
the same concentration were not activated and used as a control. Molt-3 cells, with or without
PMA stimulation were incubated with anti-LFA-1-FITC (0, 0.05 and 0.1 mg/ml) at 4 °C for
45 min. Free antibodies were removed by rinsing three times with PBS after centrifugation
(595 g, 1.5 min). The fluorescent intensity of cells was analyzed by flow cytometry. In addition,
the specificity of anti-LFA-1-FITC was confirmed by incubation with A549 cells, which
express ICAM-1 but not LFA-1. A549 were cultured as previously reported. 23 Molt-3 cells
co-express LFA-1 and ICAM-1. Both cells were incubated with 0.4 μM of PMA at 37°C for
20 hrs. Anti-LFA-1-FITC (0.05 mg/ml) was incubated with Molt-3 cells for 45 min at 4°C.
Cells were washed three times with PBS and centrifuged (595 g,1.5 min) The fluorescent
intensity of Molt-3 cells was determined by using a FACscan flow cytometer. Data analysis
was performed using Cell Quest software (BD).
2.4 Binding and uptake of cIBR-NPs into Molt-3 cells—The binding and uptake of
cIBR-NPs encapsulated fluorescent dye was studied by using flow cytometry. PMA stimulated
Molt-3 cells (1 × 106 cells/ml) were added in a 96 well-plate (200 μl/well) containing CaCl2
(1.5 mM) and incubated with cIBR-NPs or NPs encapsulating coumarin-6 (2.2 mg/ml, 90 μl)
at 37 °C for 5, 15, 20 and 35 min. Cells were then repeatedly centrifuged (460 g, 4°C for 1
min) and washed three times with cold PBS and fixed with 4% paraformaldehyde. The
fluorescent intensity of cells was measured using the FACscan flow cytometer. Data analysis
was performed using Cell Quest software (BD). To investigate whether the uptake was
dependent on the nanoparticle concentration, Molt-3 cells (1 × 106 cells/ml, 100 μl) in serum
free media were added to a 96 well-plate containing CaCl2 (1.5 mM) followed by incubation
with cIBR-NPs (70 μl/well) at 37 °C for 30 min at various concentrations (0.08, 0.16, 0.33,
0.66, 1.31, 2.63, 5.25 and 10.50 mg/ml). Cells were washed three times with cold PBS by
centrifugation at 460 g, 4°C for 1 min. The fluorescent intensity of the Molt-3 cells was again
determined using the FACscan flow cytometer. Data analysis was performed as before.
2.5 Inhibition of the binding of cIBR-NPs—cIBR-NPs were hypothesized to bind to the
I domain of LFA-1, a binding site of cIBR peptide. 14-16 The binding site of cIBR-NPs was
studied by blocking with cIBR. LFA-1 on Molt-3 (4 × 104 cells/ml) was stimulated by PMA
(0.4 μM) for 20 hrs. Cells were added to a 96-well plate (100 μl) containing CaCl2 (1.5 mM).
Free cIBR at various concentrations (0.0, 0.31, 0.63, 1.2 and 2.5 mg/ml, 80 μl) was incubated
with cells for 40 min at 4°C to inhibit the binding of cIBR-NPs or NPs to LFA-1. Cells were
then incubated with cIBR-NPs or untargeted NPs (2.2 mg/ml, 80 μl) at 4°C for 40 min. Cells
were rinsed three times with cold PBS by centrifugation (460 g, 1 min, 4°C), fixed with 4%
paraformaldehyde and again analyzed by flow cytometry.
To further investigate whether the binding site of cIBR-NPs is LFA-1 I domain or not, free
LFA-1 I domain was used to block the binding of cIBR-NPs to LFA-1 on plasma membrane
of Molt-3 cells. The LFA-1 I domain was dissolved in water at various concentrations, 0, 0.31,
0.63 1.25 and 2.50 mg/ml and was mixed with cIBR-NPs (2.1 mg/ml, 80 μl) at 37 °C for 1 hr.
After incubation, Molt-3 cells (1× 106 cells/ml) were added (100 μl) into the mixture and
incubated at 37 °C for 40 min. Cells were pelleted by centrifugation (460 g, 1 min, 4°C) and
free cIBR-NPs and the I domain were removed by three centrifugation/washing cycles. Cells
were fixed using 4% paraformaldehyde. The binding of cIBR-NPs to the cells was determined
from the fluorescent intensity analyzed by flow cytometry using the specified data analysis.
Inhibition of cIBR-NP uptake was also investigated by incubating BSA (0, 0.31, 0.63 1.25 and
2.50 mg/ml) with cIBR-NP (2.1 mg/ml, 80 μl) at 37 °C for 1 hr. Albumin is known to adsorb
to hydrophobic particle surfaces and was used here to determine if albumin could non-
specifically block ligand interactions with receptors. After incubation, Molt-3 cells (1× 106
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cells/ml) were added (100 μl) into the mixture and incubated at 37 °C for 40 min to allow
binding of cIBR-NP to LFA-1 of cells. Free cIBR-NP and BSA were washed three times with
PBS. Cells were fixed with 4% paraformaldehyde. The binding of cIBR-NP to the cells was
determined from the fluorescent intensity analyzed by flow cytometry.
2.6 Temperature effects on the binding and internalization of cIBR-NPs and NPs
—The energy-dependent internalization of cIBR-NPs into Molt-3 cells was investigated in this
study. LFA-1 on Molt-3 cells (1.1 × 106 cells/ml) were activated by PMA (0.4 μM) for 20 hrs
at 37 °C and cells were then added to a 96 well plate (100 μl/well) and incubated with serum
free medium containing 1.5 mM CaCl2 for 40 min at 4°C and 37°C followed by incubation
with cIBR-NPs or NPs (2.2 mg/ml, 90 μl/well) for 5, 15, 25, 35 and 45 min. Cells were then
washed three times with PBS and fixed with 4% paraformaldehyde. The uptake of cIBR-NPs
or NPs by cells was determined from the fluorescent intensity analyzed using flow cytometry
as before.
2.7 Fluorescence microscopy of the uptake of cIBR-NPs by Molt-3 cells—
Fluorescence microscopy was performed to compare the extent of binding and uptake of cIBR-
NPs and untargeted NPs in Molt-3 cells. Molt-3 cells (1 × 106 cells/ml) were activated by using
0.4 μM PMA for 24 hrs. Cells were then added to an 8-well plate containing CaCl2 (1.5 mM).
cIBR-NPs or NPs (2.2 mg/ml) were incubated with the cells for 5, 15, 30 min and 1 hr at 37°
C, 5% CO2. Unbound nanoparticles were removed by washing three times with cold PBS and
fixed with 4% paraformaldehyde. Fluorescence micrographs were acquired using the FITC
filter set of a Nikon Eclipse 80i microscope equipped for epifluorescence. Micrographs were
captured using an Orca ER camera (Hamamatsu, Inc., Bridgewater, NJ) and analyzed by
Metamorph, version 6.2 (Universal Imaging Corp., West Chester, PA)
2.8 Lysosomal trafficking of cIBR-NPs in Molt-3 cells—Fluorescence microscopy was
utilized to investigate the intracellular fate of cIBR-NPs and untargeted NPs in Molt-3 cells.
Molt-3 cells (1 × 106 cells/ml) were activated with 0.4 μM of PMA for 20 hrs. Cells were
washed and dispersed in Texas red dextran (Mw 10,000, lysine fixable, 1 mg/ml) in serum free
media and incubated for 2 hrs at 37°C, 5% CO2. Cells were washed three times with serum
free medium. Cells were then incubated in serum free media at 37°C, 5% CO2 for 12 hrs to
allow the dye to traffic lysosomes. Cells were then added to an 8 well plate containing CaCl2
(1.5 mM). Then cIBR-NPs or NPs (100 μl, 2.2 mg/ml) were added to cells and incubated for
10 min at 37°C, 5% CO2. Unbound nanoparticles were removed by washing three times with
serum free medium. Cells were then incubated in serum free medium for each time period (30
min, 1 hr, 2 hrs, 3 hrs, 4 hrs, 6 hrs, 8 hrs and 24 hrs.). Cells were washed by centrifugation at
856 g for 1 min and fixed with 4% paraformaldehyde. Fluorescence emissions of nanoparticles
and lysosomes were observed using FITC and rhodamine filter sets, respectively (Nikon
Eclipse 80i microscope equipped for epifluorescence). Micrographs were captured using an
Orca ER camera (Hamamatsu, Inc.). Colocalization of nanoparticles with lysosomes were
analyzed by Metamorph, version 6.2.
2.9 Inhibition of heterotypic adhesion by cIBR-NPs—cIBR-NPs were hypothesized
to bind to LFA-1 of Molt-3 cells, hence blocking the binding of LFA-1 of Molt-3 cells and
ICAM-1 of A549 lung epithelial cells. The inhibition of LFA-1 and ICAM-1 adhesion by cIBR-
NPs was monitored in this study. A549 cells (8 × 105 cells/ml) were incubated with TNF-α
(1,000 U/mL) for 48 hrs to activate the expression of ICAM-1 as reported previously. 23 LFA-1
on Molt-3 cells was activated by 0.4 μM of PMA in serum free medium for 20 hrs. Molt-3
cells were labeled with a fluorescent dye, 2′,7′-bis-(2-carboxyethyl)-5-(and-6)-
carboxyfluorescein, acetoxymethyl ester (BCECF, AM) (5 μl, 2 mM), in 20 ml of PBS for 15
min at 37°C. Cells were washed three times with PBS and resuspended in 5 ml of PBS (final
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concentration of cells was 5.5 × 105 cells/ml). Molt-3 cells were then transferred to a 96-well
plate (200 μl/well) and incubated with various concentrations of cIBR-NPs (0, 0.38, 0.75 and
1.50 mg/ml) at 37°C for 30 min. Molt-3 cells were then transferred to A549 culture on 8 well
plates to evaluate the interaction between ICAM-1 on A549 cells and LFA-1 on Molt-3 cells
at 37°C, 5% CO2 for 45 min. After incubation, unbound Molt-3 cells were washed away with
cold PBS three times and the culture was fixed with 4% paraformaldehyde. The binding of
Molt-3 to A549 cells was quantified by counting the bound Molt-3 in four images taken with
the Nikon Eclipse 80i microscope.
2.10 Statistical analysis—Statistical evaluation of data was performed using an analysis
of variance (one-way ANOVA). Newman–Keuls was used as a post-hoc test to assess the
significance of differences. To compare the significance of the difference between the means
of two groups, a t-test was performed; in all cases, a value of p < 0.05 was accepted as
significant.
3. Results
3.1 PLGA nanoparticle preparation and characterization
PLGA nanoparticles were prepared using a solvent displacement method. 23 Nanoparticles
were formed from PLGA, which served as a hydrophobic core to encapsulate the poorly water
soluble dye, coumarin-6. 23 The diameter of nanoparticles was approximately 200 nm with a
low polydispersity suggesting a narrow size distribution. Modified Pluronic ® F -127 bearing
carboxylic acid termini yielded negatively charged NPs. The zeta potential value was about
-23 mV (Table 1). It is probable that the strong negative charge provided some electrostatic
stabilization to reduce agglomeration and maintain particle size. Furthermore, free carboxylic
acid groups on the modified surfactant allowed conjugation of the targeting peptide.
3.2 Conjugation of cIBR peptide to PLGA-nanoparticles
The cIBR peptide was covalently attached to the carboxylic acid end groups of modified
Pluronic® F-127 on the nanoparticle surface using carbodiimide chemistry. 23 The conjugation
efficiency was determined by quantifying the unconjugated ligand remaining in the reaction
medium after nanoparticle separation. The amount of cIBR peptide conjugated on NP measured
by RP-HPLC increased during the reaction (0-20 hrs) (Fig. 1A). The peptide density on the
surface of nanoparticles after reaction was calculated assuming a normal Guassian particle size
distribution (Table 2). 23 The conjugation reaction was also performed in the absence of EDC
to observe any possible adsorption (electrostatic or hydrophobic interaction) of cIBR peptide
to the nanoparticles. The result showed that the adsorption of peptide was negligible since the
amount of peptide conjugated with NP analyzed by RP-HPLC did not increase when peptide
was incubated with nanoparticles without activation of COOH (Fig. 1B).
3.3 PMA stimulates aggregation of Molt-3 cells
Molt-3 cells were found to aggregate in response to PMA (Fig. 2A). Although a small amount
of homotypic adhesion of Molt-3 cells also occurred in the absence of PMA, PMA stimulated
Molt-3 cells exhibited much larger cell clusters. In previous reports, PMA was shown to
increase the avidity of LFA-1 via rhoA protein which works as an intracellular transducer of
protein kinase C activation leading to integrin activation and cell aggregation. 24
Immunofluorescence flow cytometry showed that the expression of LFA-1 on Molt-3 cells was
not changed when incubated with PMA suggesting that PMA did not induce expression of
LFA-1 (Fig. 2B). This result was previously observed in other LFA-1 bearing cells. 25 As a
control, A549 lung carcinomic epithelial cells, expressing ICAM-1, but not LFA-1 were
incubated with PMA and also incubated with anti-LFA-1-FITC. The fluorescent intensity
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measured by flow cytometry was negligible compared with Molt-3 cells since A549 cells lack
LFA-1 (Fig. 2C).
3.4 cIBR-NPs exhibit interaction with Molt-3 cells
The binding and uptake of cIBR-NPs by Molt-3 cells were monitored using flow cytometry.
The interaction of cIBR-NPs and Molt-3 cells was substantially greater than that of untargeted
NPs (Fig. 3A). Molt-3 cells showed ∼5 fold higher fluorescence when incubated with targeted
nanoparticles. The fluorescent intensity of Molt-3 cells increased with time for both particle
types but to a larger extent for cIBR-NPs. These results suggested that cIBR-NPs bound to
Molt-3 cells more quickly and to a greater extent when compared to untargeted NPs.
Furthermore, the binding of cIBR-NPs was also concentration dependent; uptake increased
with increasing nanoparticle concentration (Fig. 4).
3.5 Free cIBR and the LFA-1 I domain inhibited the binding of cIBR-NPs to Molt-3 cells
Inhibition of cIBR-NPs was investigated by incubating Molt-3 cells with free cIBR peptide
followed by incubation with cIBR-NPs or NPs. The fluorescent intensity of cells incubated
with cIBR-NPs decreased significantly compared to cells incubated with untargeted NPs (Fig.
5A). Disrupting of the binding of cIBR-NPs to Molt-3 cells by cIBR peptide suggested cIBR-
NPs targeted LFA-1. The binding of untargeted NPs was again very low.
To further validate binding specificity, cIBR-NPs were allowed to bind to the I domain of
LFA-1 prior to incubation with Molt-3 cells. The I domain was expected to bind to cIBR on
targeted NPs and block the binding of targeted NPs to LFA-1 on Molt-3 cells. As the
concentration of the LFA-1 I domain increased, the binding of cIBR-NPs correspondingly
decreased (Fig. 5B). The binding of cIBR-NPs was reduced to ∼60% when 2.5 mg/ml of the
I domain was used with cIBR-NPs compared to the absence of the I domain whereas there was
no significantly reduction when the same concentration of BSA was added with cIBR-NP (Fig.
5C). This result further supported the specific binding of cIBR-NPs to the I domain of LFA-1.
Previous reports verified that cIBR peptide has a PRGG sequence with a β-turn structure similar
to the D1 of ICAM-1, the binding site of LFA-1. 14-15 Furthermore, Anderson and Siahaan
elucidated the binding specificity of cIBR peptide and showed that cIBR-FITC binding to
soluble LFA-1 can be competitively inhibited by an anti-CD11a antibody as an indicator of
specific binding of cIBR to the I domain of LFA-1. 14 This binding specificity appeared to be
maintained when conjugated to the surface of PLGA nanoparticles.
3.6 Uptake of cIBR-NPs is temperature dependent
Molt-3 cells were incubated with cIBR-NPs at 4 °C and 37 °C to determine the effect of
temperature on the uptake of nanoparticles and to learn whether the mechanism of cIBR-NPs
entry into Molt-3 cells was energy dependent. The uptake of cIBR-NPs decreased significantly
at 4 °C (Fig. 6A), suggesting that cIBR-NPs uptake was indeed energy dependent. Furthermore,
the fluorescent intensity of cells incubated with cIBR-NPs at 37 °C increased over time. At
low temperature, cIBR-NPs binding was similar to binding at 37 °C; however, the increase in
fluorescent intensity occurred more slowly suggesting that endocytosis was slowed at low
temperature. The dependence of temperature on the uptake of untargeted nanoparticles was
also investigated. The uptake of nanoparticles without peptide was also decreased at low
temperature but to a lesser extent (Fig. 6B) confirming an energy dependent endocytic process
observed previously. 26
3.7 Fluorescence microscopy of Molt-3 cells and nanoparticles
The uptake of cIBR-NPs and NPs by Molt-3 cells was examined by fluorescence microscopy.
The association of cIBR-NPs and NPs with Molt-3 cells was clearly demonstrated by
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fluorescence micrographs. The fluorescent intensity of cells incubated with untargeted NPs
was far less than cells incubated with targeted NPs (Fig. 7). The fluorescent intensity of cells
incubated with NPs slowly increased with incubation time and showed the greatest intensity
at the longest time, whereas the fluorescent intensity of cells incubated with cIBR-NPs was
quite high initially. These results supported the kinetics of cIBR-NPs incubated with Molt-3
cells determined by flow cytometry. Both suggest the rapid binding and internalization of cIBR-
NPs and may suggest receptor saturation.
3.8 Trafficking of cIBR-NPs
Lysosomes are acidic and contain hydrolytic enzymes where nanoparticles and/or encapsulated
drugs may be degraded. To investigate whether cIBR-NPs trafficked to the lysosomes or not,
fluorescent colocalization studies of lysosomes and nanoparticles were conducted. The
lysosomal compartments of Molt-3 cells were stained with Texas red-dextran (lysine fixable)
to track cIBR-NPs and NPs uptake. Then, cells were treated with cIBR-NPs or NPs
encapsulating the green fluorescent dye. The intracellular localization of nanoparticles was
tracked at different time points and lysosomal accumulation was indicated by yellow
fluorescence in merged images (Fig. 8). The colocalization of cIBR-NPs with lysosomal
vesicles may be not evident over 24 hrs. The colocalization of untargeted NPs with lysosomes
was undetectable at 6 hrs and was detected until at least 24 hrs. These results implied that
cIBR-NPs did not persist in lysosomes but untargeted NPs slowly accumulated in lysosomes.
3.9 cIBR-NPs inhibit the adhesion of Molt-3 cells and lung epithelial cells
Leukocyte recruitment to endothelial and epithelial tissues requires interaction of LFA-1 and
ICAM-1. 14, 27 cIBR peptide alone has been shown to inhibit homotypic and heterotypic cell
interactions via binding LFA-1. 17, 19, 28 The interaction of LFA-1 on PMA-stimulated Molt-3
cells and ICAM-1 expressed on lung carcinomic epithelial cells activated with TNF-α resulted
in heterotypic cell adhesion and was investigated by fluorescence microscopy. Micrographs
allowed quantification of the number of adhered Molt-3 cells (stained with a green fluorescent
dye) to A549 cells (Fig 9A). Pretreatment of Molt-3 cells with cIBR-NPs was investigated as
a means to inhibit this heterotypic cell adhesion. When PMA-stimulated Molt-3 cells were pre-
incubated with cIBR-NPs, significant inhibition was observed (Fig. 9B). Pretreatment of
Molt-3 cells with cIBR-NPs yielded up to a ∼73% decrease in adhered cells suggesting that
cIBR-NPs bound to LFA-1 of Molt-3 cells blocked the availability of LFA-1 integrins to bind
to ICAM-1 on A549 cells. Furthermore, cIBR-NPs may decrease the availability of LFA-1 on
the cell surface via endocytosis of this receptor. 14 The result of this study revealed the potential
of cIBR-NPs to inhibit lymphocyte recruitment during inflammatory responses.
4. Discussion
The interaction of LFA-1 and ICAM-1 plays a vital role in leukocyte recruitment and migration
across the vasculature during normal leukocyte circulation through lymph nodes and during
recruitment in the response to inflammatory signals. LFA-1 also participates in the
‘immunological synapse’ between T lymphocytes and antigen presenting cells (APC). 6 In
recent decades, potential therapeutic agents used to block the binding of LFA-1 to ICAM-1 to
treat immunological and inflammatory disorders have focused on monoclonal antibodies and
small molecules designed to antagonize interactions between these proteins. 29-30 However,
hypersensitivity reactions and unpredictable half-lives are often encumbrances for
immunotherapy using monoclonal antibodies. 28, 30, 31 In comparison to monoclonal
antibodies, cyclic peptides have been shown to offer improved safety, physicochemical
stability and may even improve selectivity to the targeted site. 3, 32
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cIBR, a cyclic peptide derived from domain 1 of ICAM-1, has demonstrated specific binding
to isolated LFA-1 and to the surface of T cells. 9, 10 Previous research showed that cIBR
conjugated to the fluorescent dye FITC entered cells via endocytosis; however, cIBR
conjugated to doxorubicin mainly passively diffused through the cell membrane of HL-60 cells.
28 Passive diffusion of cIBR-doxorubicin may be a result of the increased hydrophobicity of
the conjugate, a change in the conformation of the cIBR peptide after conjugation and/or steric
hindrance of doxorubicin at the recognition site of the cIBR peptide. 28 Regardless, these
findings suggested that the delivery of some drugs may be improved if the drugs were
encapsulated.
In the present study, cIBR was conjugated to the surface of PLGA nanoparticles. The physical
incorporation of drug in the particle matrix may mask the hydrophobicity of the drug and
mitigate potential off-target passive diffusion into cells driven by the poorly water soluble
compound. Furthermore, the grafting of cIBR to the end of a long chain surfactant on the
nanoparticle surface can reduce steric hindrance at the cIBR binding site which may have
occurred in a single drug-peptide conjugate28.
The importance of multivalency in the LFA-1/ICAM-1 interaction and the activation of high
avidity LFA-1 in some types of LFA-1 expressing cells have been reported. 33 LFA-1 is
exclusively expressed on leukocytes but these cells do not adhere to ICAM-1 unless activated
(e.g. by PMA). 6, 34 Furthermore, Welder et al have demonstrated that monovalent, soluble
intercellular cell adhesion molecule-1 (sICAM-1) shows only modest binding to LFA-1
expressed on cells unless it is first rendered multivalent by coupling to polystyrene
microspheres, thus, illustrating the importance of multivalency. 35 Pyszniak et al have
demonstrated that sICAM-1-coated microspheres specifically bind to activated LFA-1 but not
to the low avidity state. 34 The distribution of high avidity LFA-1 on the cell surface was
observed to be highly localized on some types of LFA-1 expressing cells, whereas the low
avidity state was more evenly distributed. They also reported that only after activation with
PMA, isolated splenic T cells and murine T cell hybrodoma T28 bound the sICAM-1
microspheres and the binding was inhibited by anti-LFA-1 mAb. Therefore, utilizing a high
density of cIBR ligands on nanoparticles may improve binding efficiency of cIBR-NPs to
activated LFA-1 due to multivalent ligand receptor interactions.
When compared to untargeted nanoparticles, grafting cIBR peptide to biodegradable PLGA
nanoparticles increased selectivity, the rate, and the extent of binding and internalization by
activated LFA-1 on acute lymphoblastic leukemia T cells (Molt-3). The uptake of targeted
nanoparticles was concentration and temperature dependent suggesting receptor-mediated
endocytosis. The partial inhibition of nanoparticle uptake at low temperature (4 °C) suggested
that the internalization of the cIBR-NPs likely occurred via an energy dependent endocytic
pathway.
Lysosomes are acidic intracellular compartments that contain a variety of hydrolytic enzymes.
Texas red-dextran is internalized by fluid phase endocytosis and accumulates in lysosomes due
to its acid hydrolase-resistant nature. 36 The fate of nanoparticles was investigated by studying
the colocalization of nanoparticles and lysosomes via fluorescence microscopy. It might be
that there was no colocalization of cIBR-nanoparticles and lysosomes was observed suggesting
that LFA-1 targeted nanoparticles do not traffic to lysosomes. The internalization and recycling
of LFA-1 to the plasma membrane has been reported. 37 The exocytosis cycle of several types
of integrins has also been shown in polymorphonuclear cells including neutrophils. 37 The
recycling process of integins is functional to retrieve these receptors and, as they cleave their
ligands, to recycle them as adhesion molecules on the plasma membrane. 37 It is possible that
cIBR-NPs bound to LFA-1 may enter this receptor recycling process. 37 Regardless, cIBR-
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NPs may have advantages over untargeted NPs for drug delivery because they can avoid
hydrolytic degradation in lysosomes.
5. Conclusion
Targeted drug delivery has emerged as an important strategy to improve the efficacy and reduce
the adverse effects of drugs. In the present study, cIBR-NPs were characterized as a potential
drug delivery system targeting the receptor, LFA-1 integrin, on leukocytes. cIBR-NPs were
bound and internalized by LFA-1 on Molt-3 T-cells much more rapidly and to a greater extent
than untargeted nanoparticles. Furthermore, cIBR-NPs bound specifically to LFA-1 on the
Molt-3 cell line as confirmed by competitive inhibition assays. cIBR-NPs did not appear to
traffic to lysosomal compartments suggesting that encapsulating drugs in this type of NPs may
offer some protection from lysosomal degradation. The adhesion between T cells and lung
epithelial cells expressing LFA-1 and ICAM-1, respectively was significantly inhibited by
cIBR-NPs. These studies suggest the plausibility of using LFA-1 as a target molecule with the
potential of a dual therapeutic effect by blocking leukocyte recruitment and targeting
immunomodulators or anti-inflammatory drugs to leukocytes.
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(A) Measurement of cIBR peptide reacted with nanoparticles over the time. The amount of
cIBR peptide conjugated on nanoparticle surface increased with incubation time indicating
reaction to nanoparticles. (B) The amount of peptide on nanoparticle was constant when the
reaction was performed without EDC. Data are presented as mean ± S.D. (n = 3), *** indicates
p < 0.001, ** indicates p < 0.01 and * indicates p < 0.05.
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(A) Stimulation of LFA-1 on Molt-3 cells by PMA. Aggregation of PMA stimulated Molt-3
cells was evident compared to unstimulated Molt-3 cells. (B) Binding of anti-LFA-1 to LFA-1
on stimulated and unstimulated LFA1-1. Anti-LFA-1-FITC labeling of LFA-1 revealed that
the expression of LFA-1 was unchanged for PMA-stimulated compared to unstimulated Molt-3
cells. (C) Negligible fluorescent intensity of anti-LFA-1-FITC was observed when incubated
with cells lacking LFA-1 (A549 cells). Data are presented as mean ± S.D., (n = 3), * indicates
p < 0.001 compared to 0 mg/ml of anti-LFA-1-FITC.
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(A) Binding of cIBR-NP to Molt-3 cells. cIBR-NP interaction with Molt-3 cells was
significantly greater than untargeted NPs at all time points. The fluorescence of Molt-3 cells
incubated with cIBR-NPs increased with time. Data are presented as mean ± S.D. (n = 3), *
indicates p < 0.001.
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The dependence of cIBR-NP concentration on the binding to Molt-3 cells. The normalized
fluorescence of Molt-3 cells increased as the concentration of cIBR-NPs increased.
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(A) The inhibition of cIBR peptide to the binding of cIBR-NP to Molt-3 cells. The interaction
of cIBR-NPs with Molt-3 cells decreased as free cIBR peptide concentration increased
suggesting that cIBR competitively inhibits binding to LFA-1 on Molt-3 cells. Data are
presented as mean ± S.D. (n = 3), ** indicates p < 0.001. (B) The inhibition of LFA-1 I domain
to the binding of cIBR-NP to Molt-3 cells. The interaction of cIBR-NPs with Molt-3 cells was
also competitively inhibited by the I domain of LFA-1. The I domain was added to the NPs
prior to addition of cells. Data are presented as mean ± S.E., (n = 3), * indicates p < 0.05. (C)
The uptake of cIBR-NP pretreated with BSA by Molt-3 cells did not decrease in the presence
of BSA.
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The dependence of temperature on the binding of cIBR-NP to Molt-3 cells. The binding and
uptake of (A) cIBR-NPs and (B) NPs were slowed at low temperature (4 °C), which suggested
energy dependent endocytosis of nanoparticles. Data are presented as mean ± SD., (n = 3), *
indicates p < 0.05, ** indicates p < 0.01 and *** indicates p < 0.001.
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Micrograph of Molt-3 cells incubated with cIBR-NP or NP encapsulating fluorescence dye.
Interaction of cIBR-NPs with Molt-3 cells occurred more quickly and to a greater extent
compared to untargeted NPs at each incubation time as shown by fluorescence micrographs.
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Micrographs of Molt-3 cells incubated with cIBR-NP or NP in the presence of Texas red-
dextran. Intracellular trafficking of cIBR-NPs and NPs (green) to lysosomal compartments
(red) of Molt-3 cells. The colocalization (yellow fluorescence) of cIBR-NPs with lysosomes
was generally not observed over 24 hrs, whereas colocalization of NPs with lysosomes was
first observed at 6 hrs and slowly increased over 24 hrs.
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The inhibition of cIBR-NP to the interaction of LFA-1 and ICAM-1 on Molt-3 cells and A549
cells. (A) Optical micrographs of the adhesion of Molt-3 cells (green) to A549 lung epithelial
cells at various concentrations of cIBR-NPs. (B) cIBR-NPs inhibited the heterotypic adhesion
of Molt-3 cells to A549 cells in a dose dependent manner. Data are presented as mean ± S.D.,
(n = 3), * indicates p < 0.001 compared with 0 mg/ml of cIBR-NPs.
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Table 1





Zeta potential value (mV)
[Mean ± SD]
NP 199 ± 8.0 0.08 ± 0.04 -22.5 ± 1.4
cIBR- NP 248 ± 10 0.08 ± 0.05 -25.7 ± 1.8
Values are representative of three experiments.
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Table 2







cIBR-NP 248 18.1 39.0 ± 9.6
Values are representative of three experiments (mean ± S.D.)
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